176 related articles for article (PubMed ID: 19536777)
1. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
Wu JY; Shih JY; Yang CH; Chen KY; Ho CC; Yu CJ; Yang PC
Int J Cancer; 2010 Jan; 126(1):247-55. PubMed ID: 19536777
[TBL] [Abstract][Full Text] [Related]
2. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
Shih JY; Gow CH; Yu CJ; Yang CH; Chang YL; Tsai MF; Hsu YC; Chen KY; Su WP; Yang PC
Int J Cancer; 2006 Feb; 118(4):963-9. PubMed ID: 16152581
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
5. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
Hotta K; Kiura K; Toyooka S; Takigawa N; Soh J; Fujiwara Y; Tabata M; Date H; Tanimoto M
J Thorac Oncol; 2007 Jul; 2(7):632-7. PubMed ID: 17607119
[TBL] [Abstract][Full Text] [Related]
11. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
12. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
15. Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
Soh J; Toyooka S; Ichihara S; Fujiwara Y; Hotta K; Suehisa H; Kobayashi N; Ichimura K; Aoe K; Aoe M; Kiura K; Date H
Int J Cancer; 2007 Sep; 121(5):1162-7. PubMed ID: 17487844
[TBL] [Abstract][Full Text] [Related]
16. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Kuwako T; Imai H; Masuda T; Miura Y; Seki K; Yoshino R; Kaira K; Utsugi M; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Ishizuka T; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Cancer Chemother Pharmacol; 2015 Oct; 76(4):761-9. PubMed ID: 26254024
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
Masago K; Fujita S; Togashi Y; Kim YH; Hatachi Y; Fukuhara A; Nagai H; Sakamori Y; Mio T; Mishima M
Clin Lung Cancer; 2011 Jan; 12(1):56-61. PubMed ID: 21273181
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC
Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137
[TBL] [Abstract][Full Text] [Related]
20. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
